MedTrace Logo

A Study of Gemcitabine Plus Nab-paclitaxel With or Without FG-3019 in Participants With Locally Advanced, Unresectable Pancreatic Cancer

NCT02210559 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 37

Last updated 2023-03-02

Study results available
· View outcomes & findings →

Summary

This is a Phase 1/2 trial to evaluate the safety, tolerability, and efficacy of FG-3019 administered with gemcitabine and nab-paclitaxel in the treatment of locally advanced, unresectable pancreatic cancer.

Conditions

  • Pancreatic Cancer (Unresectable)

Interventions

DRUG

FG-3019

FG-3019 will be administered per dose and schedule specified in the arm group description.

DRUG

Gemcitabine

Gemcitabine will be administered per dose and schedule specified in the arm group description.

DRUG

Nab-paclitaxel

Nab-paclitaxel will be administered per dose and schedule specified in the arm group description.

Sponsors & Collaborators

  • FibroGen

    lead INDUSTRY

Principal Investigators

  • Vincent Picozzi, MD · Virginia Mason Medical Center - Benaroya Research Institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-07-31
Primary Completion
2021-12-15
Completion
2021-12-15

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02210559 on ClinicalTrials.gov